Audubon-based Globus Medical has announced its acquisition of California life sciences company Nevro Corp. for $250 million ...

Jefferies analyst reiterated a Buy rating for Globus Medical (NYSE:GMED), with a steady price target of $105.00, following the company's announcement of its plans to acquire Nevro Corp . (NYSE:NVRO), ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Audubon, PA-based Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions for patients with musculoskeletal disorders. The company currently has its ...

Analyst Ryan Zimmerman from BTIG maintained a Buy rating on Globus Medical (GMED – Research Report) and keeping the price target at $91.00. Ryan Zimmerman’s rating is based on a combination of ...

Globus Medical GMED has seen impressive momentum in the past year, with its shares soaring 62.1%. It has significantly outperformed the industry’s 7.3% rise and the S&P 500 composite’s 24.8% gain.

Globus Spirits shares zoomed 17 per cent in Monday's trade on BSE, logging an intraday high at Rs 930.9 per share. The buying interest in the stock sparked after the company said the Ministry of ...

Audubon, PA-based Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions for patients with musculoskeletal disorders. The company currently has its ...

The average surprise for the last two quarters was 18.99%. For the last reported quarter, Globus Medical came out with earnings of $0.83 per share versus the Zacks Consensus Estimate of $0.65 per ...